Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers. The Global Resource for Advancing Cancer Education (GRACE) is committed to providing the knowledge that will help enable the general public to be informed participants in their own care. Visit for more info.

Lung cancer patients with the EGFR mutation who had progressed on other drugs did well on a new drug in clinical trial, though one particular side effect concerns some.

Results from recent clinical trials looking into PD1 inhibitors of kidney cancer are giving patients and doctors reasons to be hopeful.

Fibroblast growth factor receptor (FGFR) mutations may play a role in the growth of squamous cell lung cancer. Dr. Jonathan Riess talks about what they are learning in this area.

Direct download: GRACEcast-229_Lung-Video_IASLC_Riess_FGFR_Role_Squamous_LC.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PDT

EGFR positive lung cancer patients who had seen cancer progression responded well to a new drug in an early clinical trial.

Direct download: GRACEcast-237_Lung-Video_ASCO_2014_AZD9291_Resistance_EGFR.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PDT

"HSP 90 inhibitors are a really cool class of drugs..." states Dr. Melissa Johnson of the Robert H. Lurie Comprehensive Cancer Center as she describes what researchers are learning about these drugs still in early development. February 2014.

Direct download: GRACEcast-228_Lung-Video_IASLC_Johnson_HSP90_Inhibitors.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PDT

Among kidney cancer patients, the sub-type "non-clear cell" is the least common. As a result, not much research has been conducted on it.

Dr. Leena Gandhi of Dana-Farber Cancer Institute sees great potential in immune therapies for lung cancer. In this video, she expresses her hope and excitement for what the future may hold. February 2014.

An analysis of two large studies of EGFR lung cancer patients tried to determine if Gilotrif helped patients live longer.

Progression-free survival is something that doctors measure to determine how well a patient responds to a particular treatment. But does it translate to increased overall survival?

A genetic mutation and a leukemia drug may provide new hope for patients with squamous cell lung cancer patients.